A retrospective study analysing overall survival in patients treated through expanded access to nivolumab in Canada

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jul 2021 Results of pooled analysis of a real world patients (n=2585)from EVIDENS and ENLARGE and a retrospective registry study evaluating Two-year survival with nivolumab in previously treated advanced non small-cell lung cancer published in the Lung Cancer
11 Jun 2020 New trial record
31 May 2020 Results of pooled analysis of real-world patients (n=2582) from NCT03382496 and NCT03382496 and from retrospective registry evaluating Two-year survival with nivolumab advanced non-small cell lung cancer, presented at the 56th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com